Pharmacy Pearls: Methylphenidate Product Shortages
January 27th, 2023 | Medication Access•Pharmacy PearlsIn an effort to assist providers in navigating shortages of Methylphenidate products, the AHP/URMC Pharmacy team is providing our network’s primary care providers with guidance on available alternatives, dosage recommendations, and alternative regimens.
Reports of Methylphenidate (Concerta®) product shortages have begun to emerge in the marketplace. Patriot, a subsidiary of Janssen and manufacturer of the generic product, will discontinue the generic product at the end of January 2023; however, Janssen will continue to manufacture the brand name, Concerta®. The discontinuation of the generic product is having a negative supply impact on the market and putting pressure on other generic manufacturers. Other oral extended-release forms remain sporadically available. Brand names tend to be available, but cost and coverage remain a challenge for some patients.
Additional Medication Shortage Updates:
- Amoxicillin Suspension product lines seem to be improving as well as their availability at local pharmacies.
- Liquid generic Acetaminophen products are still having supply line issues with intermittent availability.
- Amphetamine Salt products continue to have limited and variable availability, even among pharmacies of the same chain. This is predominantly affecting the Extended Release products.
- GLP-1 Receptor Agonist shortages remain due to increased demand and supply chain issues.
As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.
Reload document 
Open in new tab 
